World Health Organization Raises Warning Over Severe Scarcity of Weight-Loss Jabs

Fewer than a tenth of individuals who could benefit from GLP-1 drugs including Wegovy are able to get them, states the World Health Organization as it releases its first advice on the medications.

Given over a billion people worldwide currently obese, it is urging broader and more equitable availability to GLP-1 medication.

Per forecasts, more than two billion will be living with obesity by 2030 if no action is taken.

"The latest guidance affirms that excess weight is a chronic disease that can be managed with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and distribution challenges are key hurdles to broad availability to the jabs that can help people shift considerable weight, says the organization.

Skinny Jab Supply Crisis

Even in the current most favorable case, the supply of such drugs might only reach about 100 million people – fewer than 10% of the global need, according to the health organization.

The advice urges countries and companies to increase availability, through measures such as licensing agreements.

A patent on the active ingredient – the core ingredient of a leading brand – is due to expire in several nations in 2026.

The Way Weight-Loss Injections Work

These medications imitate a biological compound to slow digestion, curb appetite and increase satiety so people reduce food intake.

Patients typically see weight reduction after several weeks of commencing the regular doses.

Evidence suggests users may put most of the weight back on a year later of halting the medication, as their normal food cravings return.

To be carrying excess weight elevates your likelihood for developing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some cancers.

Obesity concerns people in all nations and was associated with millions of deaths worldwide in 2024, per the WHO.